StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
TTNP opened at $5.15 on Thursday. Titan Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $13.97. The stock’s 50 day simple moving average is $6.50 and its 200 day simple moving average is $6.83.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- MarketBeat Week in Review – 7/1 – 7/5
- What Are Dividend Achievers? An Introduction
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Qualcomm Stock Continues to Rise in the Face of Negative News
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.